Insmed reported $-89833000 in Operating Profit for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Profit Change
DBV Technologies DBVT:US -16771000 3.29M
Acelrx Pharmaceuticals ACRX:US $ -8995000 820K
Alimera Sciences ALIM:US $ -4.15M 1.4M
Biomarin Pharmaceutical BMRN:US $ 137.33M 203.21M
Cytokinetics CYTK:US $ -80.55M 58.85M
Dynavax Technologies DVAX:US $ 30.76M 49.95M
Gilead Sciences GILD:US $ 197M 743M
Heron Therapeutics HRTX:US $ -62.92M 9.39M
Insmed INSM:US $ -89833000 9.24M
Mirati Therapeutics MRTX:US $ -184.22M 12.86M
Novartis NVS:US $ 2852M 290M
Ophthotech OPHT:US $ -34.67M 1.57M
Regeneron Pharmaceuticals REGN:US $ 1258.5M 1381.2M
Sarepta Therapeutics SRPT:US $ -86.88M 18.93M
Seattle Genetics SGEN:US $ -133.05M 39.02M
Ultragenyx Pharmaceutical RARE:US $ -136.63M 34.07M
Vertex Pharmaceuticals VRTX:US $ 1040.9M 163.18M